After H.C. Wainwright and Cantor Fitzgerald gave Evolus Inc (NASDAQ: EOLS) a Buy rating last month, the company received another Buy, this time from Mizuho Securities. Analyst Irina Rivkind Koffler reiterated a Buy rating on Evolus Inc today and set a price target of $31. The company’s shares closed yesterday at $24.38.
Rivkind Koffler noted:
“We reiterate our Buy rating and $31 PT after an uneventful quarter. We expect more visibility on the Jeuveau commercial plan, pricing, and market dynamics at the May 8 Analyst Day.”
According to TipRanks.com, Koffler is a 4-star analyst with an average return of 5.5% and a 39.5% success rate. Koffler covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries Limited, Bausch Health Companies Inc, and Assertio Therapeutics Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Evolus Inc with a $33.60 average price target, implying a 37.8% upside from current levels. In a report issued on April 26, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $35 price target.
See today’s analyst top recommended stocks >>
Based on Evolus Inc’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $12.44 million. In comparison, last year the company had a GAAP net loss of $6.16 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. It offers products under the brand of Jeuveau. The company was founded in November, 2012 and is headquartered in Newport Beach, CA.
